antivector
immun
recogn
potenti
caveat
use
virusbas
vaccin
present
studi
alphavirusbas
replicon
particl
vaccin
platform
demonstr
robust
immunogen
anim
model
test
effect
antivector
immun
immunogen
hemagglutinin
influenza
viru
target
antigen
efficaci
protect
lethal
challeng
viru
chimer
alphavirusbas
replicon
particl
compris
venezuelan
equin
enceph
viru
nonstructur
sindbi
viru
structur
compon
induc
effici
protect
antibodi
respons
advers
influenc
multipl
immun
vector
express
variou
antigen
ver
last
decad
replicationdefect
viral
vector
draw
attent
vaccin
research
field
altern
deliveri
system
antigen
address
shortcom
classic
vaccin
strategi
inactiv
subunit
attenu
vaccin
alphavirus
among
viral
vector
develop
undergo
clinic
test
due
part
abil
stimul
humor
cellular
mucos
immun
respons
alphavirus
belong
togavirida
famili
contain
positivesens
singlestrand
rna
genom
approxim
kb
encod
four
nonstructur
protein
twothird
genom
follow
strong
subgenom
promot
direct
express
viral
structur
protein
onethird
genom
upon
infect
cell
alphaviru
nonstructur
protein
immedi
translat
form
polymeras
complex
initi
replic
viral
genom
highlevel
transcript
subgenom
promot
translat
downstream
structur
protein
gene
product
lead
assembl
progeni
viral
particl
vaccin
deliveri
vector
base
alphavirus
develop
semliki
forest
viru
sfv
sindbi
sin
viru
venezuelan
equin
enceph
vee
viru
also
vector
chimera
incorpor
desir
properti
sin
vee
alphaviru
vector
modifi
rna
genom
subgenom
code
region
structur
protein
replac
one
antigen
encod
sequenc
modif
allow
cytoplasm
replic
rna
vector
render
defect
de
novo
viral
particl
format
lack
structur
protein
alphaviru
vector
refer
replicon
replicon
use
form
dna
plasmid
dna
vaccin
altern
defect
replicon
rna
packag
viruslik
particl
alphaviru
capsid
envelop
structur
protein
particl
replicon
particl
produc
provid
structur
protein
replicon
rna
cultur
product
cell
replicon
particl
shown
highli
effici
elicit
antigenspecif
immun
respons
varieti
anim
model
viral
vector
vaccin
platform
gener
preexist
antivector
immun
respons
host
may
becom
complic
issu
consid
use
vectorbas
platform
gener
vaccin
strategi
inde
shown
vaccin
use
vaccinia
viru
vector
fail
induc
strong
immun
respons
presenc
antivector
immun
case
adenoviru
vector
interfer
preexist
antivector
neutral
antibodi
vigor
discuss
although
controversi
find
report
veebas
replicon
particl
shown
antive
antibodi
induc
particl
interfer
induct
protect
immun
induc
replicon
particl
base
vector
express
differ
gene
interest
although
neutral
titer
vector
shown
report
recent
alphavirusbas
vaccin
strategi
test
clinic
set
one
studi
report
immun
veebas
replicon
particl
could
success
break
toler
selfantigen
tumorspecif
antigen
despit
induct
vectorspecif
neutral
antibodi
studi
evalu
veesin
chimerabas
replicon
particl
express
influenza
viru
hemagglutinin
ha
altern
vaccin
strategi
tradit
influenza
subunit
vaccin
prepar
despit
exist
neutral
antivector
immun
induc
administr
replicon
particl
encod
unrel
antigen
higher
dose
condit
use
other
show
haexpress
replicon
particl
still
abl
gener
strong
humor
antibodi
respons
ha
antigen
protect
mice
lethal
challeng
influenza
viru
seed
stock
strain
reassort
vaccin
strain
gener
apuerto
bulk
lot
monoval
subunit
influenza
vaccin
prepar
deriv
strain
good
manufactur
practic
guidelin
provid
product
depart
novarti
vaccin
diagnost
srl
antigen
concentr
measur
content
ha
prepar
seed
stock
strain
kindli
provid
r
dougla
nation
institut
medic
research
unit
kingdom
propag
seed
stock
embryon
chicken
egg
titrat
standard
procedur
allanto
fluid
collect
aliquot
store
gener
veesin
replicon
particl
obtain
sequenc
encod
ha
influenza
strain
viral
seed
process
rna
extract
use
rneasi
kit
qiagen
germani
extract
rna
subsequ
revers
transcrib
follow
pcr
use
primer
sequenc
end
ha
code
region
parent
use
design
pcr
primer
amplifi
dna
fragment
clone
pbluescript
vector
stratagen
la
jolla
ca
avoid
select
sequenc
contain
mutat
incorpor
pcr
consensu
sequenc
ha
segment
determin
multipl
clone
sequenc
ident
consensu
sequenc
strain
transfer
vector
replicon
particl
deriv
ha
sequenc
refer
similarli
ha
nucleoprotein
np
sequenc
transfer
vector
replicon
particl
produc
construct
refer
veesinnp
respect
cdna
encod
sever
acut
respiratori
syndrom
sar
spike
protein
genbank
access
number
also
subclon
vector
prepar
replicon
particl
express
sarsspik
protein
veesinssp
hn
gene
js
strain
deriv
strain
gener
synthet
also
insert
alphaviru
replicon
vector
produc
replicon
particl
respect
gener
purif
qualiti
control
replicon
particl
perform
describ
elsewher
immun
challeng
experi
femal
balbc
balb
canncrl
mice
purchas
age
week
charl
river
laboratori
calco
itali
replicon
particl
dilut
appropri
concentr
phosphatebuff
salin
pb
group
mice
immun
intramuscular
im
rout
l
replicon
particl
infecti
unit
iu
mous
interv
challeng
experi
week
last
immun
l
viru
solut
contain
mous
lethal
dose
mld
live
influenza
viru
inocul
nostril
mld
mous
total
without
anesthesia
surviv
challeng
mice
monitor
day
infect
immunogen
experi
serum
prepar
blood
immun
mice
week
immun
serolog
analys
veesinssp
particl
administ
iumous
three
four
time
interv
hyperimmun
induc
antivector
immun
follow
immun
iumous
replicon
particl
twice
interv
week
prime
boost
experi
group
balbc
mice
immun
im
administr
three
time
either
inactiv
viru
g
per
dose
iu
per
dose
group
given
two
booster
immun
vee
data
present
serum
endpoint
antibodi
titer
mean
group
shown
horizont
bar
see
fig
rabbit
immun
two
set
new
zealand
white
rabbit
use
two
prime
dose
administ
im
week
follow
two
booster
dose
im
week
one
group
rabbit
receiv
subtypeb
dna
prime
im
protein
boost
im
group
immun
prime
boost
im
follow
primeboost
regimen
effect
preexist
antivector
neutral
evalu
administr
three
addit
dose
iu
per
dose
particl
week
anim
monitor
daili
basi
euthan
exhibit
defin
human
endpoint
bodi
weight
loss
preestablish
studi
agreement
novarti
anim
welfar
polici
elisa
circul
influenza
ha
sarsspik
antibodi
titrat
endpoint
enzymelink
immunosorb
assay
elisa
coat
plate
nunc
roskild
denmark
monoval
subunit
vaccin
prepar
deriv
gml
recombin
spike
protein
sar
coronaviru
sarscov
gml
gml
serial
dilut
sera
ad
coat
block
elisa
plate
bound
antiha
antisarsspik
antibodi
detect
alkalin
phosphataseconjug
goat
antimous
igg
southern
biotechnolog
associ
birmingham
al
follow
pnitrophenylphosph
pnpp
substrat
sigmaaldrich
st
loui
mo
bound
antibodi
detect
peroxidaseconjug
goat
antimous
southern
biotechnolog
associ
al
follow
ophenylenediamin
dihydrochlorid
opd
substrat
sigmaaldrich
st
loui
mo
antibodi
titer
express
reciproc
dilut
give
optic
densiti
nm
od
mean
od
blank
well
plu
three
standard
deviat
sd
blank
consist
display
od
variabl
evalu
level
antivector
antibodi
highthroughput
assay
develop
util
cell
stabli
transfect
report
activ
veesin
replicon
particleencod
nonstructur
protein
assay
test
sera
heat
inactiv
h
duplic
sampl
serial
dilut
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
fc
penicillin
streptomycin
sera
incub
iu
multipl
infect
moi
veesin
replicon
particl
express
green
fluoresc
protein
gfp
h
room
temperatur
sampl
use
infect
report
cell
seed
cell
per
well
plate
infect
sampl
incub
co
h
follow
addit
dmem
contain
fc
overnight
incub
co
assay
plate
control
includ
background
well
cell
ad
veesingfpsera
well
cell
infect
iu
veesingfp
approxim
hour
postinfect
cell
prepar
evalu
use
galactolight
plu
appli
biosystem
foster
citi
ca
chemiluminesc
report
gene
assay
assay
cell
supernat
remov
cell
rins
pb
lyse
use
provid
buffer
frozen
report
assay
complet
follow
manufactur
recommend
briefli
ml
lysat
ad
ml
galactolight
plu
dilut
buffer
plu
galactonplu
incub
min
room
temperatur
time
ml
acceler
ad
luminos
determin
trilux
luminomet
report
rel
light
unit
rlu
result
rlu
test
sampl
convert
percent
inhibit
use
formula
inhibit
experiment
rlu
background
rlu
total
rlu
background
rlu
total
rlu
read
cultur
well
infect
iu
veesingfp
serum
dilut
result
inhibit
calcul
interpol
hiv
neutral
assay
neutral
antibodi
titer
assess
use
base
neutral
assay
neutral
titer
highest
serum
dilut
rel
luminesc
unit
rlu
reduc
compar
measur
viru
control
well
serum
sampl
subtract
background
rlu
western
blot
purifi
particl
control
cell
lyse
ripa
buffer
thermo
scientif
rockford
il
accord
manufactur
instruct
extract
protein
separ
electrophoresi
use
criterion
xt
bistri
precast
polyacrylamid
gel
biorad
hercul
ca
protein
extract
iu
replicon
particl
g
total
cell
lysat
load
gel
protein
separ
gel
transfer
nitrocellulos
membran
use
iblot
gel
transfer
stack
iblot
apparatu
invitrogen
carlsbad
ca
membran
incub
dilut
mous
antisera
follow
incub
dilut
horseradish
peroxidas
hrp
conjug
goat
antimous
antibodi
perkinelm
waltham
blot
treat
supersign
west
pico
chemiluminesc
substrat
thermo
scientif
rockford
il
membran
expos
amersham
hyperfilm
ecl
ge
healthcar
limit
unit
kingdom
visual
haspecif
band
statist
statist
analysi
antibodi
titer
log
transform
test
normal
distribut
use
kolmogorovsmirnov
test
continu
variabl
geometr
mean
antibodi
titer
gmt
confid
interv
ci
deriv
antilog
mean
mean
sd
log
titer
transform
first
test
whether
chimer
replicon
particl
inde
protect
anim
lethal
challeng
live
influenza
viru
aw
mice
prepar
chimer
replicon
particl
ha
sequenc
viru
vaccin
balbc
mice
twice
iu
mice
protect
influenza
viru
challeng
data
shown
subsequ
studi
vaccin
mice
either
twice
iu
two
week
final
vaccin
mice
challeng
intranas
dose
mld
viru
group
mice
receiv
one
two
dose
iu
complet
protect
lethal
influenza
viru
challeng
within
group
mice
vaccin
twice
iu
anim
die
day
challeng
note
unlik
one
mous
die
day
challeng
die
due
challeng
sinc
model
take
day
influenza
viru
caus
death
moreov
follow
one
vaccin
iu
two
vaccin
iu
mice
partial
protect
lethal
challeng
vaccin
iu
protect
mice
fig
base
data
mice
vaccin
twice
iu
vee
replicon
particl
determin
effect
preexist
antivector
immun
effect
hyperimmun
replicon
vector
protect
follow
vaccin
lethal
challeng
order
induc
antivector
immun
prior
immun
subclon
sequenc
encod
spike
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
antigen
unrel
ha
chimer
vector
prepar
replicon
particl
express
sarsspik
protein
veesinssp
hyperimmun
induc
immun
respons
variou
compon
replicon
particl
includ
vee
viru
nonstructur
protein
antienvelop
sin
antibodi
expect
neutral
cellular
entri
replicon
particl
upon
replicon
particl
immun
sin
envelop
glycoprotein
suppli
molecul
associ
particl
synthes
de
novo
infect
tissu
vivo
although
adjuv
effect
could
expect
rna
replic
event
upon
particl
infect
amount
administ
envelop
glycoprotein
replicon
particl
antigen
much
lower
found
standard
protein
immun
reason
vaccin
mice
im
replicon
particl
repeatedli
three
time
week
high
dose
ie
iumous
highest
feasibl
produc
dose
laboratori
hyperimmun
mice
vaccin
twice
interv
iumous
particl
observ
mice
vaccin
veesinssp
particl
protect
anim
control
group
vaccin
pb
fig
moreov
possibl
antivector
immun
might
crossprotect
influenza
viru
infect
may
exclud
mice
vaccin
veesinnp
replicon
particl
suscept
influenza
viru
lethal
challeng
data
shown
interfer
antivector
immun
induc
humor
immun
respons
replicon
particl
vaccin
due
lack
reagent
studi
immunogen
ha
protein
influenza
strain
repeat
abovedescrib
experi
influenza
strain
vaccin
mice
im
veesinssp
replicon
particl
dose
iumous
four
time
week
detect
high
titer
antisarsspik
antibodi
immun
anim
indic
vaccin
success
fig
mice
subsequ
vaccin
im
iu
particl
prepar
ha
sequenc
haspecif
antibodi
titer
sera
anim
use
evalu
suppress
effect
prior
hyperimmun
interestingli
anim
vaccin
veesinssp
yield
immun
respons
specif
protein
high
anim
control
group
vaccin
pb
fig
sinc
infect
mice
measur
hemagglutin
inhibit
hi
titer
evalu
product
function
antibodi
instead
perform
challeng
experi
although
immun
particl
mice
ie
one
hyperimmun
control
mice
show
hi
titer
show
margin
hi
activ
serum
hyperimmun
mice
develop
signific
serum
hi
activ
similar
detect
sera
pb
control
mice
vee
particl
immun
tabl
vector
neutral
titer
vari
howev
correl
alphaviru
neutral
titer
haspecif
elisa
titer
order
exclud
possibl
ha
contamin
particl
prepar
would
potenti
abl
induc
antiha
immun
respons
perform
western
blot
experi
confirm
detect
ha
protein
replicon
particl
even
larger
iu
administ
mous
fig
one
possibl
explan
unaffect
humor
respons
hyperimmun
mice
immun
veesinssp
fail
mount
neutral
antibodi
vivo
sin
viru
envelop
protein
chimer
replicon
particl
util
infect
address
possibl
analyz
sera
neutral
titer
infect
chimer
replicon
particl
vitro
surprisingli
anim
possess
suffici
number
neutral
antibodi
prevent
infect
replicon
particl
vitro
tabl
data
indic
preexist
antivector
immun
interfer
protect
immun
respons
immun
use
alphaviru
replicon
vector
next
sought
addit
support
lack
preexist
antivector
effect
immun
respons
follow
vaccin
vector
bear
differ
antigen
purpos
determin
whether
three
prime
im
vaccin
would
result
decreas
serum
antibodi
respons
two
subsequ
im
vaccin
ie
veesin
vector
express
instead
found
statist
signific
differ
serum
respons
group
vaccin
three
time
im
inactiv
compar
group
vaccin
fig
b
assess
effect
preexist
antivector
respons
differ
speci
anim
vaccin
im
group
rabbit
four
prime
dose
follow
three
im
boost
dose
addit
second
group
rabbit
also
vaccin
im
three
dose
second
group
rabbit
previous
vaccin
two
dose
dna
follow
two
dose
protein
serv
control
group
vectorpreexpos
rabbit
elicit
strong
antiha
antibodi
respons
fig
follow
four
prime
vaccin
rabbit
first
group
induc
high
titer
antibodi
envelop
well
high
level
antivector
neutral
respons
data
shown
data
show
vaccin
mice
rabbit
veesin
replicon
particl
encod
one
antigen
caus
decreas
serum
antibodi
titer
new
antigen
follow
subsequ
vaccin
veesin
replicon
particl
encod
new
antigen
number
public
evalu
alphavirusbas
replicon
particlebas
vaccin
immunogen
well
protect
efficaci
varieti
infecti
agent
includ
human
immunodefici
viru
cytomegaloviru
respiratori
syncyti
viru
measl
viru
parainfluenza
viru
influenza
viru
furthermor
veesin
replicon
particl
demonstr
higher
cellular
immun
respons
sin
virusbas
replicon
particl
use
gag
protein
human
immunodefici
viru
chimer
replicon
particl
use
present
studi
also
abl
show
improv
humor
respons
compar
sin
viru
replicon
particl
see
tabl
supplement
materi
success
demonstr
protect
immun
respons
differ
preclin
studi
veesin
replicon
particl
two
major
advantag
characterist
first
chimer
replicon
particl
express
replicas
vee
viru
known
less
sensit
type
interferon
ifn
thu
enabl
replic
effici
sin
virusbas
replicon
particl
mechan
like
lead
larger
amount
protein
express
gene
interest
consequ
chimer
rep
serum
neutral
titer
determin
inhibit
infect
bhk
cell
hemagglutin
inhibit
hi
assay
known
give
valu
correl
protect
use
evalu
protect
serum
immun
antigen
deriv
viru
infect
anim
hyperimmun
group
treat
four
time
iu
veesinssp
replicon
particl
control
group
mice
treat
pb
immun
licon
particl
offer
stronger
antigen
present
host
immun
system
second
envelop
protein
chimer
replicon
particl
deriv
sin
viru
point
mutat
effici
infect
dendrit
cell
dc
therefor
use
chimer
replicon
particl
also
add
advantag
immunogen
sinc
dc
pivot
profession
antigenpres
cell
replicon
rna
start
replic
host
cell
form
doublestrand
rna
intermedi
ligand
tolllik
receptor
tlr
signal
tlr
lead
product
interleukin
upstream
cytokin
lead
ifn
secret
turn
lead
subsequ
cytotox
cell
respons
scenario
immun
activ
replicon
particl
thu
natur
immun
system
mimick
viral
infect
without
caus
actual
diseas
although
high
potenc
alphaviru
replicon
particl
advantag
induc
better
protect
immun
robust
immun
respons
might
induc
antivector
immun
would
reduc
vaccin
efficaci
administ
repeatedli
present
studi
address
issu
set
challeng
immun
condit
select
high
lethal
challeng
dose
mld
mous
influenza
viru
determin
immun
dose
ensur
detect
decreas
efficaci
due
antivector
immun
observ
vaccin
rel
small
dose
replicon
particl
enough
protect
lethal
challeng
rel
excess
dose
influenza
viru
fig
protect
replicon
particl
dose
depend
challeng
dose
data
shown
therefor
possibl
reduc
immun
dose
mice
challeng
lower
viru
dose
viru
administ
without
anesthesia
order
target
infect
upper
respiratori
tract
replicon
particl
also
protect
mice
challeng
anesthesia
infect
lower
respiratori
tract
data
shown
robust
immunogen
induc
alphaviru
replicon
particl
shown
present
studi
well
past
report
offer
potenti
benefit
immunodefici
individu
newborn
elderli
individu
immunosuppress
condit
efficaci
veebas
replicon
particl
immatur
immun
system
demonstr
chicken
embryo
young
bird
data
lead
hypothesi
alphaviru
replicon
particl
may
also
good
altern
induct
effect
immun
respons
immunocompromis
individu
henc
test
alphaviru
replicon
particl
differ
age
group
mammal
warrant
interfer
preexist
antivector
immun
vaccin
efficaci
one
import
obstacl
applic
viral
vector
vaccin
deliveri
system
exampl
signific
proport
human
popul
alreadi
antibodi
number
adenoviru
serotyp
broad
seropreval
human
popul
may
limit
applic
vector
case
alphavirus
virus
commonli
infect
human
popul
individu
neg
antialphaviru
immun
furthermor
present
studi
use
ha
influenza
viru
vaccin
antigen
show
repetit
immun
chimer
replicon
particl
induc
antivector
immun
wherea
efficaci
vaccin
affect
fig
although
contamin
ha
protein
detect
replicon
particl
prepar
use
immun
still
possibl
argu
trace
amount
protein
incorpor
particl
might
suffici
induc
immun
respons
howev
absenc
adjuv
subunit
vaccin
prepar
yield
specif
antiha
igg
respons
high
replicon
particlebas
immun
see
tabl
supplement
materi
moreov
accident
store
dri
ice
day
lost
infect
immun
mice
fail
induc
specif
humor
immun
respons
ha
data
shown
data
observ
suggest
presenc
neutral
antibodi
veesin
vector
sin
envelop
affect
induct
antibodi
ha
encod
replicon
particl
also
confirm
lack
effect
antivector
immun
use
differ
antigen
combin
fig
differ
anim
speci
fig
rhesu
macaqu
could
also
boost
increas
immun
respons
multipl
administr
replicon
particl
although
effect
antivector
immun
directli
address
thu
alphaviru
replicon
particl
may
applic
human
multipl
administr
without
decreas
efficaci
characterist
particular
advantag
pathogen
influenza
virus
often
chang
antigen
antigen
drift
antiinfluenza
vaccin
must
prepar
accord
predict
outbreak
everi
year
moreov
alphaviru
replicon
particl
platform
suitabl
prepar
vaccin
influenza
pandem
handl
part
genet
materi
aggress
influenza
strain
similar
revolutionari
revers
genet
rg
approach
rg
use
live
virus
although
suppos
attenu
isol
subunit
protein
step
produc
infecti
influenza
viru
replicon
platform
approach
therefor
grant
safeti
prepar
vaccin
viruslik
particl
vlp
constitut
anoth
potenti
vaccin
platform
technolog
similar
safeti
replicon
platform
influenza
viru
produc
although
product
vlp
requir
gene
influenza
viru
ha
na
result
support
studi
demonstr
newborn
anim
possess
matern
antive
viru
neutral
antibodi
success
mount
antidengu
immun
respons
immun
veebas
replicon
particl
express
dengu
viru
antigen
recent
studi
demonstr
multipl
administr
alphaviru
replicon
particl
induc
vector
neutral
respons
function
antibodi
product
gene
interest
encod
vector
howev
studi
antivector
immun
elicit
immun
respons
gene
product
interest
simultan
present
studi
directli
address
effect
preexist
antivector
immun
possibl
argu
hyperimmun
induc
antivector
immun
vitro
neutral
might
attribut
rather
antibodi
molecul
function
receptor
alphaviru
entri
fact
replicon
particl
prepar
use
bhkv
cell
cell
line
deriv
cell
use
sin
neutral
assay
present
studi
directli
exclud
possibl
carryov
receptor
molecul
product
cell
line
particl
prepar
howev
detect
antibovin
serum
antigen
bsa
antibodi
particleimmun
mous
sera
data
shown
particl
prepar
elimin
bsa
major
compon
cultur
media
antibsa
antibodi
induc
immun
mice
less
like
antibodi
molecul
like
cellular
receptor
induc
replicon
particl
stimul
host
immun
system
presenc
antialphaviru
neutral
antibodi
one
possibl
explan
site
immun
muscl
tissu
access
neutral
antibodi
anoth
possibl
molecul
involv
hostparticl
interact
vivo
may
vitro
known
tissu
express
fc
receptor
could
instrument
antibodymedi
alphaviru
particl
entri
target
cell
could
bypass
viral
receptormedi
infect
vivo
recent
report
show
alphaviru
replicon
migrat
quickli
drain
lymph
node
administr
author
specul
dc
muscl
tissu
may
play
role
migrat
although
discuss
whether
dc
circumv
particl
neutral
antivector
antibodi
understand
exact
mechan
studi
microenviron
site
particl
administr
includ
local
express
viral
encod
protein
kinet
inflammatori
cell
recruit
would
also
requir
although
safeti
issu
alphavirus
vaccin
vector
address
paper
also
critic
clinic
applic
platform
state
pathogen
effect
observ
upon
replicon
particl
immun
present
studi
notic
earli
death
challeng
group
immun
iu
fig
group
hyperimmun
anim
iu
veesinssp
follow
iu
fig
sign
advers
effect
caus
particl
immun
think
unlik
case
dose
depend
even
anim
pb
control
group
die
day
challeng
independ
experi
data
shown
consid
earli
death
event
may
associ
handl
anim
challeng
otherwis
observ
neither
abnorm
behavior
patholog
sign
anim
vaccin
replicon
particl
recent
clinic
safeti
studi
vee
replicon
particl
show
one
seriou
advers
event
associ
studi
agent
observ
total
healthi
volunt
receiv
mani
iu
replicon
particl
three
time
conclus
data
demonstr
replicon
particl
use
repeatedli
preexist
antialphaviru
immun
affect
efficaci
replicon
particl
vaccin
therefor
chimer
replicon
particl
promis
vaccin
deliveri
technolog
platform
